经鼻高流量氧疗与无创通气在慢性阻塞性肺疾病急性加重中的比较
本研究为前瞻性、随机、单盲研究,将137例COPD急性加重患者分为NIV组(n=47)、HFNC-30组(n=44)和HFNC-50组(n=46),比较治疗前及治疗后30、60、120 min的动脉血气参数。三组入院时平均PaCO2无显著差异(p=0.372),所有组在30、60、120 min均出现平均PaCO2显著下降(p均<0.05)。HFNC-30组60 min时ΔPaCO2显著高于NIV组(p=0.042);插管率和28天死亡率在三组间无显著差异(p=0.368和p=0.775)。结论认为HFNC在改善COPD急性加重患者动脉血气方面不劣于NIV,30 L/min流量在60 min时降低PaCO2优于NIV。
要点
- COPD急性加重患者中,HFNC在改善PaCO2方面不劣于NIV,尤其适用于高碳酸血症患者。
- HFNC-30组60 min时ΔPaCO2显著高于NIV组(p=0.042)。
- 三组插管率无显著差异(p=0.368),28天死亡率无显著差异(p=0.775)。
- 所有治疗组在30、60、120 min均出现平均PaCO2显著下降(p均<0.05)。
适用人群与场景
- 连续纳入的137例COPD急性加重患者,其中男性90例、女性47例,平均年龄68.1 ± 10.5岁。
处置流程与药物剂量
- NIV组(n=47)接受双水平正压通气。
- HFNC-30组(n=44)接受流量为30 L/min的经鼻高流量氧疗。
- HFNC-50组(n=46)接受流量为50 L/min的经鼻高流量氧疗。
研究设计与关键结果
- 研究为前瞻性、随机、单盲研究,共纳入137例COPD急性加重患者,分为NIV组(n=47)、HFNC-30组(n=44)和HFNC-50组(n=46)。
- 总插管率为15.33%(21例),总体死亡率为10.2%。
- 入院时平均PaCO2在NIV组、HFNC-30组和HFNC-50组分别为64.69 ± 10.81、61.51 ± 9.03和62.29 ± 9.87,组间无显著差异(p=0.372)。
- 所有治疗组在30、60、120 min均出现平均PaCO2显著下降(p均<0.05)。
- 60 min时ΔPaCO2在HFNC-30组显著高于NIV组(p=0.042)。
- 插管率在三组间无显著差异(p=0.368),28天死亡率在三组间无显著差异(p=0.775)。
证据类型、等级与局限
- 证据类型:前瞻性、随机、单盲研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,HFNC在改善COPD急性加重患者动脉血气参数(尤其是PaCO2)方面不劣于NIV,尤其适用于高碳酸血症患者;且30 L/min流量的HFNC在60 min时降低PaCO2优于NIV。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We investigated the efficacy and safety of a high-flow nasal cannula (HFNC) at different flow rates compared to noninvasive ventilation (NIV) in patients with acute chronic obstructive pulmonary disease (COPD) exacerbations.
METHODS: This prospective, randomized, single-blind study assigned patients to one of three study groups. The NIV group (n = 47) received bilevel positive airway pressure. The HFNC-30 (n = 44) and HFNC-50 (n = 46) groups received HFNC therapy at flow rates of 30 and 50 L/min, respectively. Demographic and clinical characteristics and arterial blood gas parameters before and 30, 60, and 120 min after treatment were compared among the treatment groups.
RESULTS: This study included 137 consecutive patients with acute exacerbations of COPD, comprising 90 males and 47 females, with a mean age of 68.1 ± 10.5 years. A total of 21 patients (15.33 %) were intubated, and the overall mortality rate was 10.2 %. The mean PaCO2 levels on admission were 64.69 ± 10.81, 61.51 ± 9.03, and 62.29 ± 9.87 in the NIV, HFNC-30, and HFNC-50 groups, respectively, with no significant differences observed (p = 0.372). A significant reduction in mean PaCO2 was observed in all treatment groups at 30, 60, and 120 min (p < 0.05 for all). However, the ΔPaCO2 at 60 min was significantly higher in the HFNC-30 group compared to the NIV group (p = 0.042). Additionally, neither intubation rates nor 28-day mortality differed among the treatment groups (p = 0.368 and p = 0.775, respectively).
CONCLUSION: HFNC was not inferior to NIV in improving arterial blood gas parameters, particularly PaCO2 in patients with COPD exacerbations, especially those with hypercarbia. Moreover, HFNC at a flow rate of 30 L/min was superior to NIV for reducing PaCO2 levels at 60 min.
TRIAL REGISTRY: National Library of Medicine Clinical Trial Registry; No.: NCT06495086; URL: https://clinicaltrials.gov/study/NCT06495086.
参考来源
- Haciosman O, Ergenc H, Az A, et al. A high-flow nasal cannula versus noninvasive ventilation in acute exacerbations of chronic obstructive pulmonary disease. Am J Emerg Med. 2024. PMID: 39481328. doi:10.1016/j.ajem.2024.10.043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。